/stocks — the workspaceLOADING
All SMMT SEC filings, by type → · Earnings date & implied move · Search inside filings
Summit Therapeutics Inc. (SMMT) is a pharmaceutical preparations company. Piotroski F-Score 3/7. 1 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind SMMT’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2024-12-31 vs 2023-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from SMMT’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on SMMT plus an auto-SWOT — built from SMMT's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate SMMT using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has SMMT been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as SMMT tagged it: revenue us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
Projected from SMMT's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentSMMT files or announces.
SMMT has sold off after 6 of its last 8 earnings reports.
Each figure is one earnings reaction — how much SMMT moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
SMMT has traded lower after most recent earnings releases.
A more typical earnings reaction has been approximately ±12.8%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-07-23 | -7.3% |
| 2026-04-30 | -22.6% |
| 2026-02-23 | +1.1% |
| 2025-10-20 | -10.7% |
| 2025-08-11 | -10.4% |
| 2025-05-01 | +15.7% |
| 2025-02-24 | -18.1% |
| 2024-10-30 | -14.8% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
The fair-value line is SMMT’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from SMMT’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
No lawmaker has disclosed a trade in SMMT under the STOCK Act.
No tracked institution reported a position in SMMT in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| IWF iShares Russell 1000 Growth ETF | <0.01% | 2026-06-30 |
| ITOT iShares Core S&P Total US Stock Market ETF | <0.01% | 2026-06-30 |
| IWB iShares Russell 1000 ETF | <0.01% | 2026-06-30 |
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Total return including reinvested dividends, from SMMT’s adjusted closing prices. Past return is not a forecast and not investment advice.
1 of 5 estimators could run on SMMT's filings. A band needs at least 2.
One estimator is a point estimate, not a range, so no band and no valuation label are published for SMMT. Below is everything that was checked, so the refusal can be read rather than taken on trust.
No sector peer set is priced for SMMT, so sector medians could not fill the gaps.
Every refusal recorded for SMMT → · How often we decline, and why →
| Zanganeh MahkamCo-Chief Executive Officer | BUY | $50.0M | view → |
| DUGGAN ROBERT WCo-Chief Executive Officer | BUY | $50.0M | view → |
| Soni Manmeet SinghCOO and CFO | BUY | $722K | view → |
| Zanganeh MahkamCo-Chief Executive Officer | BUY | $1.5M | view → |
| DUGGAN ROBERT WCo-Chief Executive Officer | BUY | $1.5M | view → |
2 of the 2 checks that ran found nothing new for SMMT. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Head office: Miami, Florida, United States · the company’s charter and its head office are in different states.
Source: the cover page of Summit Therapeutics Inc.’s 10-Q filed 2026-07-23, on EDGAR. Filings checked 2026-10-26. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works